Trial Profile

SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semaglutide (Primary)
Indications Cardiovascular disorders; Myocardial infarction; Obesity; Stroke
Focus Registrational; Therapeutic Use
Acronyms SELECT
Sponsors Novo Nordisk

31 Mar 2025 Results of sub-analysis of SELECT trial presented in a Novo Nordisk Media Release.
17 Mar 2025 According to a Novo Nordisk media release, data from this study presented at the American College of Cardiology 74th Annual Scientific Session and Expo (ACC.25).
28 Nov 2024 According to a Novo Nordisk a media release, Wegovy (semaglutide injection) is now approved to reduce the risk of non-fatal myocardial infarction in adults with established cardiovascular disease and BMI equal to or greater than 27 kg/m2. Health Canada's non-fatal MI indication for Wegovy is based on results of this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com